Needham & Company Reiterates a 'Buy' on Cantel Medical (CMN); Raising Numbers After Another Strong Qtr

Needham & Company reiterates a 'Buy' on Cantel Medical (NYSE: CMN) price target raised from $22 to $26.

Analyst, Dalton Chandler, said, "Strong performances by three recently acquired companies helped CMN to once again beat our top and bottom line estimates. The most recent acquisition, Byrne Medical, in the Endoscope segment, is looking particularly astute as it had 30% Y/Y revenue growth and helped to improve the overall gross margin."

Needham raises FY12 EPS estimate from $0.68 to $1.10 and FY13 from $0.76 to $1.37.

For an analyst ratings summary and ratings history on Cantel Medical click here. For more ratings news on Cantel Medical click here.

Shares of Cantel Medical closed at $21.81 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Travel Food Services (TRAVELFO:IN) PT Raised to INR1,600 at ICICI Securities
• Solar Industries (SOIL:IN) PT Raised to INR23,500 at ICICI Securities